142 related articles for article (PubMed ID: 35371862)
1. Aberrant Expression of p63 in an Adenocarcinoma of the Prostate That Has Metastasized to the Oral Cavity.
Khalid R; Ramanathan A; Tee Lun H; Lim D
Cureus; 2022 Mar; 14(3):e22753. PubMed ID: 35371862
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Role of p63 in differentiating morphologically ambiguous lesions of prostate.
Baig MK; Hassan U; Mansoor S
J Coll Physicians Surg Pak; 2012 Dec; 22(12):773-7. PubMed ID: 23217483
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
5. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm.
Rathod SG; Jaiswal DG; Bindu RS
J Family Med Prim Care; 2019 Aug; 8(8):2651-2655. PubMed ID: 31548949
[TBL] [Abstract][Full Text] [Related]
7. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
8. Expression of p63 in potentially malignant and malignant oral lesions.
Sinha A; Chandra S; Raj V; Zaidi I; Saxena S; Dwivedi R
J Oral Biol Craniofac Res; 2015; 5(3):165-72. PubMed ID: 26605141
[TBL] [Abstract][Full Text] [Related]
9. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
10. Aberrant cytoplasmic expression of p63 and prostate cancer mortality.
Dhillon PK; Barry M; Stampfer MJ; Perner S; Fiorentino M; Fornari A; Ma J; Fleet J; Kurth T; Rubin MA; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):595-600. PubMed ID: 19155438
[TBL] [Abstract][Full Text] [Related]
11. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
12. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
13. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
14. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
Yaskiv O; Zhang X; Simmerman K; Daly T; He H; Falzarano S; Chen L; Magi-Galluzzi C; Zhou M
Am J Surg Pathol; 2011 Jul; 35(7):1062-8. PubMed ID: 21623182
[TBL] [Abstract][Full Text] [Related]
15. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Adenocarcinoma Metastasizing to the Oral Mucosa of the Upper Jaw.
Baranović M; Vidaković B; Sauerborn D; Perić B; Uljanić I; Mahovne I
Srp Arh Celok Lek; 2015; 143(5-6):314-6. PubMed ID: 26259405
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
Gao Q; Chen J; Dai Y
J Med Case Rep; 2018 Mar; 12(1):72. PubMed ID: 29519246
[TBL] [Abstract][Full Text] [Related]
18. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis.
Baydar DE; Kulac I; Gurel B; De Marzo A
Int J Surg Pathol; 2011 Feb; 19(1):131-6. PubMed ID: 20719821
[TBL] [Abstract][Full Text] [Related]
19. p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers.
Kalantari MR; Anvari K; Jabbari H; Tabrizi FV
Iran J Basic Med Sci; 2014 Jul; 17(7):497-501. PubMed ID: 25429340
[TBL] [Abstract][Full Text] [Related]
20. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
